Instructions for Edomari (erdosteine) 300 mg
Drug form
Edomari
Caps. 300 mg: 10 or 20 pcs.
reg. No. : LP-000990 from 18.10.11 - Indefinitely
The form of release, packaging and composition of the drug Edomari
The capsules are solid gelatin, with a yellow body and a green lid; the contents of the capsules are white to almost white powder.
1 caps.
erdosteine 300 mg
Auxiliary substances Edomari:
microcrystalline cellulose (Vivapur ® 102) - 10 mg, povidone K30 - 8 mg, magnesium stearate - 3 mg.
The composition of the capsule shell: gelatin - 74.4 mg, titanium dioxide (E171) - 0.76 mg, iron oxide yellow (E172) - 0.749 mg, indigocarmine (E132) - 0.091 mg.
10 pcs - blisters (1) - cardboard packs.
10 pcs - blisters (2) - cardboard packs.
Clinical-pharmacological group: Mucolytic drug Edomari
Pharmacotherapeutic group Edomari:
expectorant mucolytic
The pharmacological action of erdosteine can be described as follows:
Mucolytic effect: erdosteine helps break down disulfide bridges in sputum, which reduces viscosity and increases the release of respiratory secretions. It improves epithelial secretory function and speeds mucociliary transport in the respiratory tract.
Antioxidant effect: erdosteine has the ability to carry free radicals and protect the airways from the damaging effects of cigarette smoke. It also prevents the inactivation of alpha-antitrypsin, which is a natural antiprotease protective factor for the lungs.
Increased IgA concentration: Erdosteine increases immunoglobulin A (IgA) levels in the lining of the airways in patients with chronic obstructive pulmonary disease. This can help strengthen the protective function of local immunity.
Does not cause damage to the gastrointestinal tract: erdosteine does not contain free SH radicals, therefore does not have a negative effect on the gastrointestinal tract.
The therapeutic effect of erdosteine usually develops after 3 to 4 days of treatment.
ICD-10 Code Indication Edomari
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J42 Chronic bronchitis, unspecified
J44 Other chronic obstructive pulmonary disease
J45 Asthma
J47 Bronchiectasis
R09.3 Sputum
The active ingredient of Edomari is acetylcysteine Edomari.
It has a mucolytic (dissolving sputum) and anti-inflammatory effect. It helps dilute and drain viscous sputum from the airways and facilitates its discharge and purification.
The drug "Edomari" is recommended for the following diseases of the respiratory tract producing sputum viscid:
1. Acute and chronic bronchitis - inflammatory diseases of the bronchi, accompanied by the release of a large amount of thick sputum.
2. Pneumonia - infectious inflammation of the lungs, which forms a viscous sputum.
3. COPD (chronic obstructive pulmonary disease) is a progressive, obstructive pulmonary disease in which the drainage of bronchial sputum release is impaired.
4. Bronchial asthma with sputum retention - Patients with asthma may have the additional problem of impaired sputum removal from the bronchi.
5. Bronchiectasis is a chronic lung disorder in which dilation (dilation) of the bronchi develops and sputum removal is impaired.
6 Prophylaxis of pneumonia and pulmonary atelectasis after surgery—pulmonary atelectasis—is obliteration or collapse (clotting) of lung tissue, especially after surgery, and may affect sputum removal.
The drug "Edomari" can be used both in the treatment of these diseases and for their prevention. However, before using Edomari, a doctor should be consulted for dosage and duration of treatment.
Recommended dose of this drug Edomari
is 300 mg, taken by mouth 2 to 3 times a day. If improvement does not occur within 5 days of starting treatment or if the person's condition worsens, the person should see a doctor. However, it is worth noting that the method and dosing regime may vary depending on the form of release of the drug and other factors. Therefore, it is important to strictly follow the doctor's recommendations and follow the indications for use and dosing regimen specified for this particular drug.
